The 36-month beta value for TEVA is also noteworthy at 0.91. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 17 rating it as “hold,” and 5 rating it as “sell.”
The public float for TEVA is 1.13B, and at present, short sellers hold a 1.60% of that float. The average trading volume of TEVA on June 17, 2024 was 9.73M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TEVA) stock’s latest price update
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA)’s stock price has gone decline by -1.38 in comparison to its previous close of 17.40, however, the company has experienced a 2.02% increase in its stock price over the last five trading days. reuters.com reported 2024-06-13 that Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing’s syndrome.
TEVA’s Market Performance
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has experienced a 2.02% rise in stock performance for the past week, with a 2.26% rise in the past month, and a 27.77% rise in the past quarter. The volatility ratio for the week is 3.06%, and the volatility levels for the past 30 days are at 2.84% for TEVA. The simple moving average for the last 20 days is 2.14% for TEVA’s stock, with a simple moving average of 43.47% for the last 200 days.
Analysts’ Opinion of TEVA
Many brokerage firms have already submitted their reports for TEVA stocks, with JP Morgan repeating the rating for TEVA by listing it as a “Neutral.” The predicted price for TEVA in the upcoming period, according to JP Morgan is $14 based on the research report published on March 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see TEVA reach a price target of $19, previously predicting the price at $12. The rating they have provided for TEVA stocks is “Overweight” according to the report published on February 12th, 2024.
Jefferies gave a rating of “Buy” to TEVA, setting the target price at $14 in the report published on January 23rd of the current year.
TEVA Trading at 12.69% from the 50-Day Moving Average
After a stumble in the market that brought TEVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.00% of loss for the given period.
Volatility was left at 2.84%, however, over the last 30 days, the volatility rate increased by 3.06%, as shares surge +5.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.19% upper at present.
During the last 5 trading sessions, TEVA rose by +2.02%, which changed the moving average for the period of 200-days by +76.00% in comparison to the 20-day moving average, which settled at $16.84. In addition, Teva- Pharmaceutical Industries Ltd. ADR saw 64.37% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TEVA starting from Weiss Amir, who sale 12,635 shares at the price of $16.65 back on May 16 ’24. After this action, Weiss Amir now owns 5,179 shares of Teva- Pharmaceutical Industries Ltd. ADR, valued at $210,377 using the latest closing price.
Weiss Amir, the Chief Accounting Officer of Teva- Pharmaceutical Industries Ltd. ADR, sale 15,500 shares at $16.80 during a trade that took place back on May 15 ’24, which means that Weiss Amir is holding 17,814 shares at $260,417 based on the most recent closing price.
Stock Fundamentals for TEVA
Current profitability levels for the company are sitting at:
- 0.07 for the present operating margin
- 0.49 for the gross margin
The net margin for Teva- Pharmaceutical Industries Ltd. ADR stands at -0.03. The total capital return value is set at 0.04. Equity return is now at value -6.08, with -1.07 for asset returns.
Based on Teva- Pharmaceutical Industries Ltd. ADR (TEVA), the company’s capital structure generated 0.73 points at debt to capital in total, while cash flow to debt ratio is standing at 0.09. The debt to equity ratio resting at 2.7. The interest coverage ratio of the stock is 1.07.
Currently, EBITDA for the company is 4.27 billion with net debt to EBITDA at 3.85. When we switch over and look at the enterprise to sales, we see a ratio of 2.27. The receivables turnover for the company is 4.63for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.89.
Conclusion
In summary, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has had a better performance as of late. Analysts have bearish opinions on the stock, with some viewing it as a “sell” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
